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Neonatal severe hyperparathyroidism (NSHPT) is a rare disease affecting calcium metabolism and results
in severe life-treating hypocalcemia of the neonates. Diagnosis can be challenging due to variable and
nonspeciﬁc symptomatology. We are reporting on a 4-month-old female infant presenting with respi-
ratory distress and chest wall deformity. We are trying to highlight different surgical options for this rare
disease and importance of close collaboration with the pediatric endocrinologist in the treatment plan
for those patients.
 2015 The Authors. Published by Elsevier Inc. All rights reserved.Neonatal severe hyperparathyroidism (NSHPT) is a rare disorder
caused by inactivation mutations of the CaRS. These receptors
expressed in a variety of tissues including parathyroid glands, renal
tubular cells, and parafollicular cells of the thyroid gland and bones.
These receptors regulate and maintain calcium homeostasis [1e3].
Single mutation of the CaRS gene results in FHH, a benign disease
that may result in mild asymptomatic hypercalcemia that requires
no speciﬁc treatment. It is thought that a homozygous mutation
will result in NSHPT, a severe form of hypercalcemia that presents
usually in the ﬁrst few weeks of life. On the other hand, activation
mutation of the CaRS genes results in ADH [4].
Medical treatment and surgical treatment options for this dis-
ease have been highlighted in many previous publications. In this
paper we are trying to highlight the importance of the timing of theemia; CaRS, calcium-sensing
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stimulating hormone; TSH,
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Published by Elsevier Inc. All righsurgery and the use of intraoperative preservation of the para-
thyroid tissues for possible need in the future.
1. Case report
We are reporting a 4-month-old female infant admitted to the
pediatric unit at King Fahad Hospital of University of Dammamwith
respiratory distress and chest wall deformity. She has bilateral
concave deformities of the rib cage on the lateral side with costal
margin retraction giving her a bell-shaped chest (Fig. 1). This
deformity was associated with paradoxical movement of the chest
wall during breathing. Her initial chest x-ray revealed bilateral
pulmonary inﬁltration and marked demineralization of the chest
wall skeleton. The infant patient was started on intravenous anti-
biotics and oxygen supplementation to treat the bilateral pneu-
monia. She had a complete workup including serum electrolytes;
calcium and vitamin D levels were all within normal ranges. The
family reported that the patient was admitted to another hospital
outside the country at the age of 20 dayswith dehydration, lethargy,
and decreased feeding. Her bloodwork at that time showed elevated
serum calcium levels at 8.3 mmol/L (ref 2.2e2.6) and normal 25-OH
vitaminDat 12.2 ng/ml (ref 10e100). Her hypercalcemiawas treated
at that time with rehydration, low calcium formula, Lasix, and
intravenous hydrocortisone. This regime continued until her cal-
cium levelnormalized. Then, thepatientwasdischargedhomeat age
of 33days on lowcalcium formula only. The family also reported thatts reserved.
Fig. 1. Portable chestX-Rayof the patient at timeof admissiondemonstrating thebilateral
pulmonary inﬁltrations, Sever demilitarized bones and bell shaped chest deformity.
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that required a total parathyroidectomy.
At this time, the patient was admitted as pneumonia and systemic
antibiotics started with supplemental oxygen. The endocrine team
was consulted and an endocrine workup was ordered. Serum thyroid
stimulating hormone and T4 were normal. Calcium levels were
normal 9.0 mg/dl (ref. 9e11). Phosphorus was low 1.9 mg/dl (ref.
2.5e4.9), but iPTHwas very high 131 pmol/L (ref.1.5e7.2). Repeat PTH
conﬁrmedthehigh levelsat109pmol/L.Thepatienthadanultrasound
onher neck that showednormal thyroid andnone of the parathyroids
were visualized. At that point, a clinical and laboratory diagnosis of
NSHPTwasmade. After improvementof her lung function, thepatient
underwent a total parathyroidectomy through a collar neck incision
with autotransplantation of one-third of a gland in the right sterno-
mastoidmuscle. Another parathyroid glandwas cryopreserved in our
tissue bank. An intraoperative frozen section conﬁrms that all 4
specimens were parathyroid tissues. Permanent histology revealed
diffuse hyperplasia of the parathyroid tissue. Postoperatively the pa-
tient was admitted to the PICU, was kept on a calcium gluconate
infusion, and checked for serum calcium every 12 h. Post operative
iPTH level was undetectable. Episodes of hypocalcaemiawere treated
with calcium gluconate bolus over 15 min and a slow increase in the
infusion rate. Maximum intravenous calcium infusionwas 400 mg of
ca/kg/day.Over the courseof days, thepatient slowlyadvanced to feed
and oral calcium and vitamin D supplementation increased as the
infusion decreased at day 13 postop patient was off calcium infusion,
at that timeSerumiPTHwasdetectable.Onday15postoperatively, the
patient suddenly developed progressive neck swelling. An urgent
neck ultrasound was performed and showed ﬂuid collection. The
patient was shifted to the operating room were she was explored
under anesthesia. Neck hematoma was evacuated and obvious
bleeding was identiﬁed. After few days in the PICU, the patient was
transferred to the ward on oral calcium supplementation. At a 2-
month follow-up, the patient was doing better with active calcium
level ranges between 7 and 9 mg/dl. Few months postoperatively
patient was on and off oral calcium supplementation with high cal-
cium formula. At age of 9 months patient serum calcium levelmaintained at low normal value on oral calcium supplementation,
iPTH level is detectable at lower than normal value 1.11 pmols/L
reference range (1.58e7.2).
2. Discussion
Neonatal Sever Hyperparathyroidism is a rare disorder caused
by inactivation mutations of the extracellular CaRS. These receptors
are expressed in many tissues including parathyroid glands, renal
tubular cells, and parafollicular cells of the thyroid gland and bones.
These receptors regulate and maintain calcium hemostasis [1e3].
Single mutation of the CaRS gene results in FHH, a benign disease
that may result in mild asymptomatic hypercalcemia that requires
no speciﬁc treatment. It is thought that a homozygous mutation
will result in NSHPT, a severe form of hypercalcemia that presents
usually in the ﬁrst few weeks of life. On the other hand, activation
mutation of the CaRS genes results in ADH [4].
Hypercalcemia in NSHPT is usually very severe and can be fatal.
Diagnosis of SNHPT is usually challenging; patients can present with
very non-speciﬁc symptoms such as lethargy, seizures, hypotonia,
respiratory distress, failure to thrive, and/or dehydration. High index
of suspension is a key for early diagnosis. Failure to establishdiagnosis
early may result in signiﬁcant complications such as neuro-
development delay, skeletal deformities, renal failure, and neph-
rocalcinosis. Serum calcium levels are usually elevated but can be
normal such as our patient’s were. Elevated serum intact parathyroid
hormone level is usually diagnostic. Serum phosphate levels are
usually low and the vitamin D level (25-OH cholecalciferol) is usually
normal as well. Neck imaging in the form of ultrasound or nuclear
scan is usually not helpful andmay delay the deﬁnitive treatment [5].
Renal ultrasound can be helpful in detecting nephrocalcinosis.
Treatment of SNHPT can be classiﬁed into three stages. The ﬁrst
stage includes acute stabilization of the patient. Intravenous ﬂuid
resuscitation is themainstay of treatment. Intravenous pamidronate
is a useful adjunct if hypercalcemia persists, it reduces the bone
resorption. More recently, calcimimetics agents such as cinacalcet
have been used successfully in some cases of NHPT. Cinacalcet in-
creases CaRS afﬁnity to calcium, which improves the function of the
mutant receptors and subsequent decrease in parathyroid hormone
secretion [6,7]. Wilhem-Bals et al. described successful use of cina-
calcet for 6 years with incremental increase of dose. Cinacalcet may
work in some mutations but not all [6]. The second stage of treat-
ment is the deﬁnitive treatment of NSHPT. Surgery remains as the
most effective intervention that is associated with better long-term
calcium level stabilization [5,8]. Surgery may vary from total para-
thyoidectomy with or without autotransplantation and 3.5 glands
removal. Al-Shanafey et al. [5] reported the biggest series from
one center where 5 patients underwent total parathyroidectomy
with auto transplant on half a gland in the forearm. A follow-up of
1e9.5 years showed that all were alive and 4 of them required cal-
ciumandvitaminD supplementation.Oneof the patients had failure
of an autotransplanted graft and none of them developed graft
dependant hypercalcemia. Total parathyroidectomy without auto-
transplantation was tried on early practice with good initial control
of the disease but lifelong hypocalcaemia and calcium supplemen-
tation was invariably needed [9,10]. Cryopreservation of the
removed parathyroid glands can be useful in this disease. The pre-
served glands can be used if the initial autotransplantation was not
successful [11] or banked for future research and genetic testing. The
third stage of treatment is postoperative control of severe hypo-
calcaemia and bone hunger. Our patient required a signiﬁcant dose
of calcium infusion ranging between 200 and 400 mg/kg/day of
elemental calcium together with vitamin D supplementation. An
episode of hypocalcaemia can be treated with intermittent boluses.
Correction of magnesium and phosphate is needed.
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and the patient transitioned to oral calcium supplementation. We
believe that close monitoring in an intensive care unit post-
operatively is needed given how fragile infant patients are.3. Conclusions
NSHPT is a rare disease that requires a high index of suspicion
and very good history to make an early diagnosis and avoid
complications. Medical treatment is helpful in stabilizing the pa-
tient and bridges him or her to the deﬁnitive surgical treatment
once the overall condition has improved. We believe that total
parathyroidectomy remains the most effective long-term treat-
ment. Heterotrophic parathyroid autotransplantation of one-
quarter or one-third of a gland might save the patient from long-
term calcium supplementations. Cryopreservation of one of the
glands during the initial procedure can be helpful should the
transplanted gland not take. Admiring the retrospective and
relatively small numbers of case series that have been reported,
more studies with longer follow-up periods are needed to un-
derstand the disease nature better and compare different surgical
options.Disclosure
The author has nothing to disclose.References
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